PT-141 (Bremelanotide): Melanocortin Peptide Research Data

What Is PT-141?

PT-141 is the development code for bremelanotide, a synthetic cyclic peptide derived from the alpha-melanocyte-stimulating hormone family. The earliest PT-141 development literature describes it as a melanocortin agonist with activity at receptors including MC3R and MC4R, both strongly linked to central nervous system signaling rather than purely peripheral vascular biology.^[1]

That central profile is what made PT-141 mechanistically interesting: it was studied as a way to probe melanocortin circuits involved in sexual motivation and response rather than the nitric-oxide pathway targeted by sildenafil-class compounds. In other words, the compound entered the literature because researchers believed melanocortin signaling might alter behaviorally relevant endpoints through the brain, not because it behaved like a conventional vascular erectile-dysfunction drug.^[1][2]

Official FDA review materials later described bremelanotide as a synthetic heptapeptide melanocortin receptor agonist in a subcutaneous drug-device product approved in the United States in June 2019.^[7] For this article, that approval history matters for one reason only: it gives researchers an official source for pharmacokinetics, adverse-event monitoring, and label language. It does not change Remy’s research-use-only framing or UAE compliance posture.

Melanocortin Mechanism: Why PT-141 Is Not a PDE5 Analogue

The PT-141 literature repeatedly positions the compound inside the melanocortin receptor family. Molinoff et al. described receptor activity including MC3R and MC4R,^[1] while the later U.S. label adds a practical clue about receptor breadth by explicitly warning that MC1R expression on melanocytes can drive increased pigmentation.^[6] Taken together, the evidence points to a receptor class with both central and peripheral readouts.

This is why PT-141 research is usually discussed as a melanocortin-circuit probe. The developmental question was whether activating that network would alter validated endpoints in defined study populations. That framing is more accurate, and more compliance-safe, than internet shorthand that treats PT-141 as a general-purpose enhancement product. For research pages in the UAE, the distinction matters: mechanism and trial design can be discussed; consumer-style promise language should be avoided.

Human Development Path: From PT-141 Code Name to Phase 3

The human evidence base is relatively easy to map because it moves through three distinct stages. First came early proof-of-concept studies using intranasal PT-141, including the Annals of the New York Academy of Sciences paper by Molinoff et al. and the placebo-controlled 2004 International Journal of Impotence Research paper by Diamond et al.^[1][2] These studies established that the compound produced measurable human signals worth pursuing.

The second phase was subcutaneous randomized dose-finding. Clayton et al. published a placebo-controlled trial in premenopausal women that tested several dose levels and used validated endpoint tools rather than anecdotal reports.^[3] This is where the development program started to look like a modern registration track rather than exploratory physiology work.

The third phase was the pair of RECONNECT phase 3 trials, which PubMed indexes as two randomized phase 3 studies of bremelanotide in premenopausal women with hypoactive sexual desire disorder.^[4] For a research page, the key point is not to re-sell those outcomes, but to note that the phase 3 program was sufficiently persuasive for the FDA to approve a branded bremelanotide product in 2019.^[7]

Official PK and Tolerability Signals

Once PT-141 entered an approved U.S. label, the development story became much easier to reference precisely. DailyMed reports a median T_max of about 1 hour, mean terminal half-life around 2.7 hours, 21% protein binding, and a mean apparent volume of distribution of 25.0 ± 5.8 L for the approved subcutaneous formulation.^[6] Those are official reference values, not instructions for use.

Two safety observations stand out. First, transient blood-pressure increases were studied directly using ambulatory monitoring, with White et al. reporting short-lived systolic increases relative to placebo after some dose exposures in a randomized program.^[5] Second, the label explicitly notes increased pigmentation through MC1R signaling on melanocytes.^[6] Nausea is also a recurrent feature of the official safety profile.^[6]

Research-Use Handling and UAE Compliance Boundary

For Remy, the practical question is not whether PT-141 has a published literature trail; it clearly does. The real question is how to present that literature without turning a research page into a treatment page. The answer is straightforward: cite the mechanism, cite the trials, cite the official safety observations, and stop there. Do not add self-use dosing instructions, pharmacy-style promise language, or disease-treatment copy.

The existence of an FDA-approved bremelanotide product does not decide UAE category or import posture. Dubai-facing pages still need to stay inside a conservative research lane, which is why this article should be read together with Are Peptides Legal in Dubai? and Research Peptides UAE. If a researcher is looking at physical handling variables rather than literature, the relevant references are the bacteriostatic water guide and the peptide stability and storage guide.